Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Samuel Klein will present at the 82nd American Diabetes Association Scientific Sessions from June 3-7, 2022, in New Orleans, LA. He will discuss the results of a Phase 1 clinical trial for pemvidutide, a dual receptor agonist targeting obesity and NASH. The presentation is scheduled for June 6, 2022, at 4:30 pm CDT, highlighting pemvidutide's potential for significant weight loss without dose adjustments. Altimmune is committed to developing innovative peptide-based therapies for metabolic and liver diseases.
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris will present at the 5th Global NASH Congress in London on May 27, 2022. His presentation will focus on pemvidutide, a novel dual receptor agonist aimed at treating obesity and NASH. Dr. Harris will also moderate a panel on clinical endpoints in NASH trials. The event highlights Altimmune's commitment to developing innovative therapeutics in the weight loss and liver disease sectors.
Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference is set for May 24 at 7:00 am Eastern Time, available via webcast. The B. Riley Securities Institutional Investor Conference will take place on May 26 at 1:00 pm Pacific Time, featuring an in-person fireside chat. Altimmune focuses on developing novel therapeutics for obesity and liver diseases, including its lead candidate, pemvidutide (ALT-801).
Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2022, showcasing ongoing clinical developments of pemvidutide, a dual receptor agonist for obesity. Notably, interim data from the Phase 2 MOMENTUM trial is expected in Q4 2022, with 10% weight loss observed after 12 weeks. However, revenue was minimal at $0.0 million, down from $0.8 million YoY, primarily due to halted projects. R&D expenses rose to $15.1 million, leading to a net loss of $19.4 million. The company holds $180 million in cash, offering a healthy runway for future trials.
Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.
Altimmune, a clinical-stage biopharmaceutical company, announced the successful completion of enrollment in its 12-week Phase 1b trial of pemvidutide for non-alcoholic fatty liver disease (NAFLD) and the initiation of the 48-week Phase 2 MOMENTUM trial for obesity. The MOMENTUM trial aims to evaluate the safety and efficacy of pemvidutide, targeting approximately 320 non-diabetic subjects. Results from a prior Phase 1 trial indicated an average weight loss of 10.3%. Key data readouts are anticipated in Q3 and Q4 2022.
Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q4 and the full year of 2021, revealing a strong cash position of $190.3 million as of December 31, 2021. The company anticipates significant clinical data readouts over the next year, particularly from the pemvidutide (ALT-801) program, which showed promising results in weight loss and lipid reduction. The enrollment for the Phase 1b trial is over 90% complete, with data expected in Q3 2022. Revenue for Q4 2021 was $3.3 million, up from $2.3 million in Q4 2020, contributing to a net loss of $23.9 million for the quarter.
Altimmune, Inc. (Nasdaq: ALT) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), being developed for obesity and NASH. Additional developments include HepTcell™, an immunotherapeutic for chronic hepatitis B.
Altimmune, a clinical-stage biopharmaceutical company, has received FDA clearance for its IND application for the pemvidutide Phase 2 clinical trial targeting obesity. The trial is set to begin in Q1 2022, enrolling around 320 participants. Pemvidutide aims to treat obesity and has previously shown promising results, with a 10.3% average weight loss in a Phase 1 study. This trial will evaluate multiple dosages over 48 weeks, focusing on weight change and metabolic health. The company also develops treatments for non-alcoholic steatohepatitis (NASH).
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris, Chief Medical Officer, will present on pemvidutide, a dual receptor agonist targeting obesity and non-alcoholic steatohepatitis (NASH). The presentations will occur at the NASH-TAG Conference from January 6-8, 2022, in Park City, Utah. Dr. Harris will deliver an oral presentation on a placebo-controlled study of pemvidutide on January 8, 2022, at 8:10 am Mountain Time. The presentation details will be available on Altimmune's website post-conference, emphasizing the company's focus on innovative treatments for obesity and liver diseases.